Antimicrobial Activity of Quercus infectoria Gall and Its Active Constituent, Gallic Acid, against Vaginal Pathogens
AbstractVaginal infections are one of the most common reasons a woman visits a gynecologist. The increased resistance to conventional antibiotics is one of the main reasons for searching and developing new antimicrobial agents, especially those of natural origin. In traditional Persian medicine, the gall of Quercus infectoria has been claimed to eliminate vagina and cervix from excessive discharge. So, the aim of the present study was to evaluate the antimicrobial activity of ethanolic extract of Quercus infectoria gall as well as its active constituent, gallic acid, against some vaginal pathogens. In this study, the ethanolic extract of Quercus infectoria gall was obtained by maceration and standardized based on amount of gallic acid. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of this extract as well as its active compound, gallic acid, were determined against Candida spp., Gardnerella vaginalis, Escherichia coli, Staphylococcus aureus, Streptococcus agalactiae, Trichomonas vaginalis and Lactobacillus acidophilus. The results demonstrated remarkable activity of ethanolic extract of Quercus infectoria gall against investigated pathogens with MIC and MBC in the range between 0.125 mg/ml and 16 mg/ml. The most inhibitory and bactericidal activity was observed on Streptococcus agalactiae and Staphylococcus aureus. The effects of gall dried ethanolic extract on Trichomonas vaginalis showed 100 % inhibition of the parasitic growth with concentration of 800 µg/ml after 24 h incubation. The antimicrobial and anti-trichomonas activity of extract was more than gallic acid. It seems that ethanolic extract of Quercus infectoria gall could inhibit the growth of vaginal pathogens. Further preclinical and clinical studies are required to confirm the efficacy of this natural extract in vaginitis.
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol 2006;107:1195-1206.
Mashburn J. Vaginal infections update. J Midwifery Womens Health 2012;57:629-634.
Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016;214:15-21.
Li J, McCormick J, Bocking A, Reid G. Importance of vaginal microbes in reproductive health. Reprod Sci 2012;19:235-242.
Cox C, McKenna JP, Watt AP, Coyle PV. New assay for Gardnerella vaginalis loads correlates with Nugent scores and has potential in the diagnosis of bacterial vaginosis. J Med Microbiol 2015;64:978-984.
Hamad M, Kazandji N, Awadallah S, Allam H. Prevalence and epidemiological characteristics of vaginal candidiasis in the UAE. Mycoses 2014;57:184-190.
Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55:809-818.
Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002;35:1066-1070.
Borman AM, Szekely A, Linton CJ, Palmer MD, Brown P, Johnson EM. Epidemiology, Antifungal Susceptibility, and Pathogenicity of Candida africana Isolates from the United Kingdom. J Clin Microbiol 2013;51:967-972.
Goncalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol 2016;42:905-927.
Organization WH. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates 2011.
Alcaide ML, Feaster DJ, Duan R, Cohen S, Diaz C, Castro JG. The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Dis 2016;92:58-62.
Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax SE. Mixed vaginitis—more than coinfection and with therapeutic implications. Curr Infect Dis Rep 2013;15:104-108.
Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007;21:375-390.
Hirt RP, Sherrard J. Trichomonas vaginalis origins, molecular pathobiology and clinical considerations. Curr Opin Infect Dis 2015;28:72-79.
Sweet RL. Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient. Infect Dis Obstet Gynecol 2000;8:184-190.
Lin WC, Chang WT, Chang TY, Shin JW. The Pathogenesis of Human Cervical Epithelium Cells Induced by Interacting with Trichomonas vaginalis. PloS one 2015;10:e0124087.
Natto MJ, Eze AA, De Koning HP. Protocols for the Routine Screening of Drug Sensitivity in the Human Parasite Trichomonas vaginalis. Chem Biol 2015:103-110.
Serwin AB, Koper M. Trichomoniasis-an important cofactor of human immunodeficiency virus infection. Przegl Epidemiol 2013;67:47-50, 131-134.
Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis 2015;15(1):307.
Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009:Cd006055.
Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478-1486.
Han C, Wu W, Fan A, Wang Y, Zhang H, Chu Z. Diagnostic and therapeutic advancements for aerobic vaginitis. Arch Gynecol Obstet 2015;291:251-257.
Bilardi J, Walker S, McNair R, Mooney-Somers J, Temple-Smith M, Bellhouse C. Women's Management of Recurrent Bacterial Vaginosis and Experiences of Clinical Care: A Qualitative Study. PLoS One 2016;11:e0151794.
Dunne RL, Linda AD, Upcroft P, O'donoghue PJ, Upcroft JA. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003;13:239-249.
Brandolt TM, Klafke GB, Goncalves CV, Bitencourt LR, Martinez AM, Mendes JF. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Braz J Microbiol 2017;48:145-150.
Mehriardestani M, Aliahmadi A, Toliat T, Rahimi R. Medicinal plants and their isolated compounds showing anti-Trichomonas vaginalis-activity. Biomed Pharmacother 2017;88:885-893.
Aghili MH. Makhzan-al-Advia. Eds.: R. Rahimi, M.R. Shams Ardekani and F. Farjadmand. Tehran University of Medical Sciences.Tehran, Iran 2009; pp 765-766.
Vazirian M, Khanavi M, Amanzadeh Y, Hajimehdipoor H. Quantification of gallic acidin fruits of three medicinal plants. Iran J Pharm Res 2011;10:233-236.
Jorgensen JH, Washington DC. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken FC, Yolken RH. 9th ed. Manual of Clinical Microbiology:MBio 2007; pp 1152-1172.
Moon T, Wilkinson JM, Cavanagh HM. Antiparasitic activity of two Lavandula essential oils against Giardia duodenalis, Trichomonas vaginalis and Hexamita inflata. Parasitol Res 2006;99:722-728.
Diamond LS. The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 1957:488-490.
Momeni Z, Sadraei J, Kazemi B, Dalimi A. Molecular typing of the actin gene of Trichomonas vaginalis isolates by PCR-RFLP in Iran. Exp Parasitol 2015;159:259-263.
Meri T, Jokiranta TS, Suhonen L, Meri S. Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol 2000;38:763-767.
Tonkal A. In vitro antitrichomonal effect of Nigella sativa aqueous extract and wheat germ agglutinin. Med Sci 2009;16:56-61.
The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-1083.
Borges A, Abreu AC, Dias C, Saavedra MJ, Borges F, Simoes M. New Perspectives on the Use of Phytochemicals as an Emergent Strategy to Control Bacterial Infections Including Biofilms. Molecules 2016;21:25-29.
Abdul Qadir M, Shahzadi SK, Bashir A, Munir A, Shahzad S. Evaluation of Phenolic Compounds and Antioxidant and Antimicrobial Activities of Some Common Herbs. Int J Anal Chem 2017;2017:3475738.
Vermani A. Screening of Quercus infectoria gall extracts as anti-bacterial agents against dental pathogens. Indian J Dent Res 2009;20:337-339.
Suwalak S, Voravuthikunchai SP. Morphological and ultrastructural changes in the cell structure of enterohaemorrhagic Escherichia coli O157: H7 following treatment with Quercus infectoria nut galls. J Electron Microsc 2009;58:315-320.
Basri DF, Khairon R. Pharmacodynamic interaction of Quercus infectoria galls extract in combination with vancomycin against MRSA using microdilution checkerboard and time-kill assay. Evid Based Complement Alternat Med 2012;2012:493156.
Baharuddin NS, Abdullah H, Abdul Wahab WN. Anti-Candida activity of Quercus infectoria gall extracts against Candida species. J Pharm Bioallied Sci 2015;7:15-20.
Kheirandish F, Delfan B, Mahmoudvand H, Moradi N, Ezatpour B, Ebrahimzadeh F. Antileishmanial, antioxidant, and cytotoxic activities of Quercus infectoria Olivier extract. Biomed Pharmacother 2016;82:208-215.
Ou LM, He QL, Ji ZH, Li KA, Tian SG. Quantitative High-Performance Thin-Layer Chromatographic Analysis of Three Active Compounds in Gall of Quercus infectoria Olivier (Fagaceae) and Use of Thin-Layer Chromatography-2,2-Diphenyl-1-Picrylhydrazyl to Screen Antioxidant Component. JPC-J Planar Chromatogr-Mod TLC 2015;28:300-306.
Chusri S, Voravuthikunchai SP. Damage of staphylococcal cytoplasmic membrane by Quercus infectoria G. Olivier and its components. Lett Appl Microbiol 2011;52:565-572.
Hussein AO, Mohammed GJ, Hadi MY, Hameed IH. Phytochemical screening of methanolic dried galls extract of Quercus infectoria using gas chromatography-mass spectrometry (GC-MS) and Fourier transform-infrared (FT-IR). J Pharmacognosy Phytother 2016;8(3):49-59.
Shao D, Li J, Li J, Tang R, Liu L, Shi J, et al. Inhibition of gallic acid on the growth and biofilm formation of Escherichia coli and Streptococcus mutans. J Food Sci 2015;80:M1299-M305.
Borges A, Saavedra MJ, Simões M. The activity of ferulic and gallic acids in biofilm prevention and control of pathogenic bacteria. Biofouling 2012;28:755-767.
Wang C, Cheng H, Guan Y, Wang Y, Yun Y. In vitro activity of gallic acid against Candida albicans biofilms. Zhongguo Zhong Yao Za Zhi 2009;34(9):1137-1140.
Li ZJ, Liu M, Dawuti G, Dou Q, Ma Y, Liu HG. Antifungal Activity of Gallic Acid In Vitro and In Vivo. Phytother Res 2017;31:1039-1045.
Sivasankar C, Maruthupandiyan S, Balamurugan K, James PB, Krishnan V, Pandian SK. A combination of ellagic acid and tetracycline inhibits biofilm formation and the associated virulence of Propionibacterium acnes in vitro and in vivo. Biofouling 2016;32:397-410.
Quave CL, Estévez-Carmona M, Compadre CM, Hobby G, Hendrickson H, Beenken KE. Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics. PloS one 2012;7:e28737.
Lima VN, Oliveira-Tintino CD, Santos ES, Morais LP, Tintino SR, Freitas TS. Antimicrobial and enhancement of the antibiotic activity by phenolic compounds: Gallic acid, caffeic acid and pyrogallol. Microb Pathog 2016;99:56-61.